Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection

Next Previous
Trial Profile

Phase I, multi-centre, randomised, placebo-controlled, dose escalation study to assess local and systemic tolerability of therapeutic DNA plasmid pdpSC18 vaccine administered by Particle Mediated Epidermal Delivery using PowderJect ND10 delivery system in subjects with chronic hepatitis B infection

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Nov 2008

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 20 Nov 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
  • 20 Nov 2008 Actual trial completion date identified as December 2007 from ClinicalTrials.gov.
  • 04 Apr 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top